Terlipressin Versus Somatostatin/Octreotide on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage (TORCH): A Retrospective Multicenter Observational Study
Overview
- Phase
- Not Applicable
- Intervention
- Terlipressin
- Conditions
- Variceal Hemorrhage
- Sponsor
- General Hospital of Shenyang Military Region
- Enrollment
- 1682
- Locations
- 14
- Primary Endpoint
- Incidence of ICA-AKI and kidney function damage in cirrhotic patients with acute gastrointestinal bleeding
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Terlipressin and somatostatin/octreotide are the first-line choices for the treatment of acute variceal bleeding in liver cirrhosis. Acute kidney injury can develop in patients presenting with acute variceal bleeding. On the other hand, evidence suggests that terlipressin can reverse hepatorenal syndrome. It has been hypothesized that terlipressin can protect the renal function in cirrhotic patients with acute variceal bleeding, except for control of bleeding.
Investigators
Xingshun Qi
Principal Investigator
General Hospital of Shenyang Military Region
Eligibility Criteria
Inclusion Criteria
- •Cirrhotic patients who were admitted between January 2010 and December
- •A diagnosis of acute gastrointestinal bleeding.
- •Patients who received terlipressin or somatostatin/octreotide.
- •Age or sex was not limited.
- •Use of endoscopy was not limited.
- •Comorbidity was not limited.
- •Malignancy was not limited.
Exclusion Criteria
- •Renal parenchymal diseases.
- •Absence of baseline serum creatinine.
- •Absence of serum creatinine 3-5 days after terlipressin or somatostatin/octreotide.
- •Duration of terlipressin or somatostatin/octreotide was less 3 days.
- •Patients who underwent transjugular intrahepatic portosystemic shunt.
- •Patients who underwent surgical shunt, splenectomy with or without devascularization, or liver transplantation.
Arms & Interventions
Terlipressin group
Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
Intervention: Terlipressin
Somatostatin/Octreotide group
Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
Intervention: Somatostatin
Somatostatin/Octreotide group
Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
Intervention: Octreotide
Outcomes
Primary Outcomes
Incidence of ICA-AKI and kidney function damage in cirrhotic patients with acute gastrointestinal bleeding
Time Frame: Through study completion, an average of 1-2 weeks
ICA-AKI and kidney function damage
Effect of ICA-AKI and kidney function damage on in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding
Time Frame: Through study completion, an average of 1-2 weeks
In-hospital mortality
Effect of terlipressin on the in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding with ICA-AKI and kidney function damage
Time Frame: Through study completion, an average of 1-2 weeks
In-hospital mortality associated with ICA-AKI and kidney function damage